BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » market news » Page 2

Why Perinatal Stem Cells Are Gaining Momentum

February 26, 2016 By Cade Hildreth (CEO) Leave a Comment

Why Perinatal Stem Cells Are Gaining Momentum (And Other Breaking Stem Cell News)

Perinatal-Stem-Cell-SocietyRecently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).

We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!

[Read more…]

Filed Under: HSCs, MSCs, Stem Cells Tagged With: conference, cynata therapeutics, market news, perinatal, Pluristem, RoosterBio, stem cells

Did You See This Week’s Top Stem Cell News?

February 22, 2016 By Cade Hildreth (CEO) Leave a Comment

Did You See This Week's Top Stem Cell News?

We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!


Q&A Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]

Filed Under: Stem Cells Tagged With: cynata therapeutics, market news, Pluristem Therapeutics, press release, RoosterBio, stem cells

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

February 16, 2016 By Cade Hildreth (CEO) Leave a Comment

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).

To learn  more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]

Filed Under: HSCs, Stem Cells Tagged With: cell therapy, market news, military defense, Pluristem Therapeutics, press release, radiation

We Interviewed Key Stem Cell Industry Leaders (Here’s What We Learned)

February 6, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking Stem Cell News and Exclusive Interviews

In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced it is pursuing a Phase II clinical trial exploring spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of multiple sclerosis (MS).

Importantly, the Phase I trial was the first time in history that a treatment demonstrated reversal of established disability in MS patients. Therefore, we are excited to release an exclusive interview with Dr. Saud Sadiq, Chief Research Scientist for Tisch MSRCNY. [Read more…]

Filed Under: Adipose SCs, Cord Blood, MSCs, Neural Stem Cells, Stem Cells Tagged With: Cesca Therapeutics, Dr. Sadiq, interviews, market news, Tisch MSRCNY, ViaCyte

Creative Bioarray Launches New Primary Cell Products, including Human Hepatic Cells and Mouse Primary Cells

February 5, 2016 By Cade Hildreth (CEO) Leave a Comment

Creative Bioarray Launches New Primary Cell Products, Including Human Hepatic Cells and Mouse Primary Cells

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. The possibilities arising from stem cell characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology screening, and more.

To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged. One of the important segments within the stem cell research products market is primary cells products.

Today, Creative Bioarray of Shirley, New York, announced that it has expanded its product portfolio by adding new primary cells products that include human hepatic (liver) cells and mouse primary cells. To learn more, view the full press release below. [Read more…]

Filed Under: Stem Cells Tagged With: Creative Bioarray, market news, press release, primary cells, stem cells

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.